Biosite Moves European Headquarters to Switzerland
September 26 2006 - 4:00AM
PR Newswire (US)
SAN DIEGO and MORGES, Switzerland, Sept. 26 /PRNewswire-FirstCall/
-- Biosite(R) Incorporated (NASDAQ:BSTE), a research-based provider
of novel, rapid medical diagnostics, today announced the opening of
its new headquarters for its European operations in Morges,
Switzerland, near Geneva. The new headquarters will manage the
Company's sales, marketing and customer support activities in
Europe. "Biosite's presence in the European market has grown
dramatically since we opened our first international office in
France in 2003," said Gary King, vice president, international
operations. "The growth in our direct sales operations in Europe
requires a strategically located facility to support our business
strategy, particularly in the areas of marketing, clinical and
customer support." The new mailing address is: Biosite
International Sarl Rue des Vignerons, 1A Morges 1110, Switzerland
Tel: +41 21 566 70 50 Fax: +41 21 802 09 33 About Biosite
Incorporated Biosite Incorporated is a leading bio-medical company
commercializing proteomics discoveries for the advancement of
medical diagnosis. The Company's products contribute to
improvements in medical care by aiding physicians in the diagnosis
of critical diseases and health conditions. Biosite's Triage(R)
rapid diagnostics are used in more than 50 percent of U.S.
hospitals and in more than 60 international markets. Information on
Biosite can be found at http://www.biosite.com/. This press release
contains forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially
from any future results, performance or achievements expressed or
implied by such statements. Examples of forward-looking statements
are financial targets and growth objectives and also include but
are not limited to statements that are preceded by, followed by, or
that include the words "will;" "believes;" "should;" "intend;"
"anticipates;" "plans;" "expects;" "estimates;" or similar
statements. Forward-looking statements in this press release
include statements regarding Biosite's presence in the European
market and anticipated growth in sales, marketing, clinical and
customer support functions in Europe. Risks and uncertainties
include risks associated with Biosite's ability to obtain
regulatory approvals and complete other pre-market activities
needed to launch new products as currently planned, including the
MPO test, a sepsis panel, a panel for acute kidney injury and a
Protein C test; Biosite's ability to effectively promote and
achieve market acceptance of any new products; the continued growth
of the BNP market generally, including the physician office market;
and other risks associated with changing market conditions and the
effect of competition from companies with greater capital and
resources. Other risks that should be considered are detailed in
the Company's most recent Annual Report on Form 10-K and other SEC
filings. The Company disclaims, however, any intent or obligation
to update these forward-looking statements. Copies of the Company's
SEC filings are available from the Investor Relations department or
from the Company's website. Biosite(R), Triage(R) and New
Dimensions in Diagnosis(R) are registered trademarks of Biosite
Incorporated. DATASOURCE: Biosite Incorporated CONTACT: Nicole
Beckstrand, Manager, Public Relations of Biosite Incorporated,
+1-858-805-2803, Web site: http://www.biosite.com/ Company News
On-Call: http://www.prnewswire.com/comp/116737.html
Copyright
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jul 2023 to Jul 2024